Herbal hepatotoxicity: A tabular compilation of reported cases

Liver International

Volumn 32, Issue 10, 2012, Pages 1543-1556

  Teschke, Rolf ^a   Wolff, Albrecht ^b   Frenzel, Christian ^c   Schulze, Johannes ^d   Eickhoff, Axel ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

Author keywords

Herb induced liver injury; Herbal hepatotoxicity; Herbal medicine; Herbs

Indexed keywords

AYURVEDIC DRUG; BABCHI; BAI FANG; BAJIAOLIAN; BOH GOL ZHEE; CASCARA SAGRADA; CHAPARRAL; CHASO; CHINESE DRUG; CREOSOTE; DA CHAI HU TANG; EXILIS; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GOTU KOLA; GREEN TEA EXTRACT; GUARANA EXTRACT; HERBACEOUS AGENT; HERBALIFE; HYDROXYCUT; IROKO; ISABGOL; JIN BU HUAN; KAVA; LIPOKINETIX; LYCOPODIUM SIMILIAPLEX; ONSHIDO; PRO LEAN; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; UNINDEXED DRUG; VENENCAPSAN; VENOPLANT; X ELLES; XIAO CHAI HU TANG;

ARTICLE; AYURVEDA; CAUSAL ATTRIBUTION; CHELIDONIUM; CHINESE MEDICINE; COLTSFOOT; EPHEDRA SINICA; FALLOPIA MULTIFLORA; GERMANDER; HERBAL MEDICINE; HUMAN; IMPILA; LIVER TOXICITY; SENNA; TEA; VISCUM ALBUM;

DIETARY SUPPLEMENTS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 84867100985     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02864.x     Document Type: Article

References (210)

1. Licata A, Macaluso FS, Craxi A. Herbal hepatotoxicity: a hidden epidemic. Intern Emerg Med 2012; DOI: 10.1007/s11739-012-0777-x [Epub ahead of print].
2. Navarro VJ. Herbal and dietary supplement hepatotoxicity. Semin Liver Dis 2009; 29: 373-82.
3. Seeff KB. Herbal hepatotoxicity. Clin Liv Dis 2007; 11: 577-96.
4. Rabe C, Musch A, Schirrmacher P, Kruis W, Hoffmann R. Acute hepatitis induced by an aloe vera preparation: a case report. World J Gastroenterol 2005; 11: 303-4.
5. Kanat O, Ozet A, Ataegin S. Aloe vera-induced acute toxic hepatitis in a healthy young man. Eur J Intern Med 2006; 17: 589.
6. Bottenberg MM, Wall GC, Harvey RL, Habib S. Oral Aloe vera-induced hepatitis. Ann Pharmacother 2007; 41: 1740-3.
7. Yang HN, Kim DJ, Kim YM, et al. Aloe-induced toxic hepatitis. J Korean Med Sci 2010; 25: 492-5.
8. Kim SY, Yim HJ, Ahn JH, et al. Two cases of toxic hepatitis caused by arrowroot juice. Korean J Hepatol 2009; 15: 504-9.
9. Teschke R, Bahre R. Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment. Ann Hepatol 2009; 8: 258-66.
10. Nam SW, Baek JT, Lee DS, et al. A case of acute cholestatic hepatitis associated with the seeds of Psoralea corylifolia (Boh-Gol-Zhee). Clin Toxicol 2005; 43: 589-91.
11. Estes JD, Stolpman D, Olyaei A, et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003; 138: 852-8.
12. Kao WF, Hung DZ, Tsai WJ, Lin KP, Deng JF. Podophyllotoxin intoxication: toxic effect of Bajiaolian in herbal therapeutics. Hum Exp Toxicol 1992; 11: 480-7.
13. Hwang SH, Park JA, Jang YS, et al. Case of acute cholestatic hepatitis caused by the seeds of Psoralea-corylifolia. Korean J Hepatol 2001; 7: 341-4 (Article in Korean)
14. Cheung WI, Tse ML, Ngan T, et al. Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related propriety medicine. Clin Toxicol 2009; 47: 683-5.
15. Smith LW, Culvenor CCJ. Plant sources of hepatotoxic pyrrolizidine alkaloids. J Nat Prod 1981; 44: 129-52.
16. Nadir A, Reddy D, Van Thiel DH. Cascara sagrada-induced intrahepatic cholestasis causing portal hypertension: case report and review of herbal hepatotoxicity. Am J Gastroenterol 2000; 95: 3634-7.
17. Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf. J Clin Gastroenterol 1990; 12: 203-6.
18. Centers of Disease Control and Prevention. Chaparral-induced toxic hepatitis California and Texas 1992. J Am Med Ass 1992; 268: 3295-8.
19. Smith BC, Desmond PV. Acute hepatitis induced by the ingestion of the herbal medication chaparral. Aust N Z J Med 1993; 23: 526.
20. Alderman S, Goldfarb S, Malone DG. Cholestatic hepatitis after ingestion of chaparral leaf: confirmation by endoscopic retrograde cholangio-pancreatography and liver biopsy. J Clin Gastroenterol 1994; 19: 242-7.
21. Batchelor WB, Heathcote J, Wanless IR. Chaparral-induced hepatic injury. Am J Gastroenterol 1995; 90: 831-3.
22. Gordon DW, Rosenthal G, Hart J, Sirota S, Baker AL. Chaparral ingestion: the broadening spectrum of liver injury caused by herbal medications. J Am Med Ass 1995; 273: 489-90.
23. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med 1997; 157: 913-9.
24. Haller CA, Dyer JE, Ko R, Olson KR. Making a diagnosis of herbal-related toxic hepatitis. West J Med 2002; 176: 39-44.
25. Adachi M, Saito H, Kobayashi H, et al. Hepatic injury in 12 patients taking the herbal loss aids Chaso and Onshido. Ann Intern Med 2003; 139: 488-92.
26. Davies EG, Pollock I, Steel HM. Chinese herbs for eczema. Lancet 1990; 336: 117.
27. Graham-Brown R. Toxicity of Chinese herbal remedies. Lancet 1992; 340: 673.
28. Perharic-Walton L, Murray V. Toxicity of traditional Chinese herbal remedies. Lancet 1992; 340: 674.
29. Kane JA, Kane SP, Jain S. Hepatitis induced by traditional Chinese herbs: possible toxic components. Gut 1995; 36: 146-7.
30. Sanders D, Kennedy N, McKendrick MW. Monitoring the safety of herbal remedies: herbal remedies have a heterogeneous nature. Br Med J 1995; 311: 1569.
31. Yoshida EM, McLean CA, Cheng ES, et al. Chinese herbal medicine, fulminant hepatitis, and liver transplantation. Am J Gastroenterol 1996; 91: 2647-8.
32. Roulet M, Laurini R, Rivier L, Calame A. Hepatic veno-occlusive disease in newborn infant of a woman drinking herbal tea. J Pediatr 1988; 112: 433-6.
33. Ridker PM, Ohkuma S, McDermott WV, Trey C, Huxtable RJ. Hepatic venoocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements. Gastroenterology 1985; 88: 1050-4.
34. Weston CFM, Cooper BT, Davies JD, Levine DF. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J (Clin Res Ed) 1987; 295: 183.
35. Bach N, Thung SN, Schaffner F. Comfrey herb tea-induced hepatic veno-occlusive disease. Am J Med 1989; 87: 97-9.
36. Ridker PM, McDermott WV. Comfrey herbs tea and hepatic veno-occlusive disease. Lancet 1989; I: 657-8.
37. Miskelly FG, Goodyer LI. Hepatic and pulmonary complications of herbal medicine (letter). Postgrad Med J 1992; 68: 935.
38. Kamiyama T, Nouchi T, Kojima S, et al. Autoimmune hepatitis triggered by administration of an herbal medicine. Am J Gastroent 1997; 92: 703-4.
39. Georgia M. Hepatotoxicity due to Atractylis gummifera. Clin Toxicol 1988; 26: 487-93.
40. McDonnell WM, Bhattacharya R, Halldorson JB. Fulminant hepatic falure after use of the herbal weight-loss supplement Exilis. Ann Intern Med 2009; 151: 673-4.
41. Larrey D, Vial T, Pauwels A, et al. Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 1992; 117: 129-32.
42. Mostefa-Kara N, Pauwels A, Pines E, Biour M, Levy VG. Fatal hepatitis after herbal tea (letter). Lancet 1992; 340: 674.
43. Dao T, Peytier A, Galateau F, Valla A. Chronic hepatitis due to germander. Gastroenterol Clin Biol 1993; 17: 614-5.
44. Mattéi A, Rucay P, Samuel D, et al. Liver transplantation for acute liver failure after herbal medicine (Teucrium polium) administration (letter). J Hepatol 1995; 22: 597.
45. Laliberté L, Villeneuve JP. Hepatitis after the use of germander, a herbal remedy. Can Med Ass J 1996; 154: 1689-92.
46. Starakis I, Siagris D, Leonidou L, et al. Hepatitis caused by the herbal remedyTeucrium polium L. Eur J Gastroenterol Hepatol 2006; 18: 681-3.
47. Jorge OA, Jorge AD. Hepatotoxicity associated with the ingestion of Centella asiatica. Rev Esp Enferm Dig 2005; 97: 115-24.
48. Strahl S, Ehret V, Dahm HH, Maier KP. Necrotising hepatitis after taking herbal remedies. Dtsch Med Wschr 1998; 123: 1410-4.
49. Greving I, Meister V, Monnerjahn C, Müller KM, May B. Chelidonium majus: a rare reason for severe hepatotoxic reaction. Pharmacoepidemiol Drug Saf 1998; 7: S66-9.
50. Benninger J, Schneider HT, Schuppan D, Kirchner T, Hahn EG. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Gastroenterology 1999; 117: 1234-7.
51. Crijns AP, de Smet PA, van den Heuvel M, Schot BW, Haagsma EB. Acute hepatitis after use of herbal preparation with greater celandine (Chelidonium majus). Ned Tijdschr Geneeskd 2002; 146: 124-8 (Article in Dutch)
52. Hardeman E, van Overbeke L, Ilegems S, Ferrante M. Acute hepatitis induced by greater celandine (Chelidonium majus). Acta Gastroenterol Belg 2003; 71: 281-2.
53. Stickel F, Pöschl G, Seitz KH, et al. Acute hepatitis induced by Greater Celandine (Chelidonium majus). Scand J Gastroenterol 2003; 38: 565-8.
54. Bundesinstitut für Arzneimittel und Medizinprodukte (German regulatory agency). Bekanntmachung. Abwehr von Gefahren durch Arzneimittel, Stufe II, Anhörung: Schöllkraut-haltige Arzneimittel zur innerlichen Anwendung. May 6, 2005. Available at: http://www.bfarm.de/cae/servlet/contentblob/1014620/publicationFile/66198/schoellkraut-anhoerung_050505.pdf Accessed May 18, 2012
55. Rifai K, Flemming P, Manns MP, Trautwein C. Severe drug hepatitis caused by Chelidonium majus. Internist 2006; 47: 749-51.
56. Conti E, De Checchi G, Mencarelli R, Pinato S, Rovere P. Lycopodium similiaplex-induced acute hepatitis: a case report. Eur J Gastroenterol Hepatol 2008; 20: 469-71.
57. Moro PA, Cassetti F, Giugliano G, et al. Hepatitis from Greater celandine (Chelidonium majus L.): review of literature and report of a new case. J Ethnopharmacol 2009; 124: 328-32.
58. Tarantino G, Di Minno MND, Pezullo MG, et al. Drug-induced liver injury due to 'natural products' used for weight loss: a case report. World J Gastroenterol 2009; 15: 2414-7.
59. European Medicines Agency (EMA). Assessment report on Chelidonium majus L., herba. Draft. November 25, 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2011/01/WC500100940.pdf Accessed May 18, 2012
60. Teschke R, Glass X, Schulze J. Herbal hepatotoxicity by Greater Celandine (Chelidonium majus): causality assessment of 22 spontaneous reports. Regul Toxicol Pharmacol 2011; 61: 282-91.
61. Teschke R, Glass X, Schulze J, Eickhoff A. Suspected Greater Celandine hepatotoxicity: liver specific causality evaluation of published case reports from Europe. Eur J Gastroenterol Hepatol 2012; 24: 270-80.
62. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Greater Celandine hepatotoxicity: a clinical review. Ann Hepatol 2012; in press.
63. Duenas Sadornil C, Fabregas Piugtio S, Durandez R. Hepatotoxicity due to Camelia sinensis. Med Clin (Barc) 2004; 122: 677-8 (Article in Spanish)
64. Garcia-Moran S, Saez-Royuela F, Gento E. Lopez Morante A, Arias L. Acute hepatitis associated with Camellia tea and Orthosiphon stamineus ingestion. Gastroenterol Hepatol 2004; 27: 559-60.
65. Abu el Wafa Y, Benaventa Fernandez A, Talavera Fabuel A, Perez Ramos MA, Ramos-Clemente JI. Acute hepatitis induced by Camellia sinensis (green tea). An Med Interna 2005; 22: 298 (Article in Spanish)
66. Gloro R, Hourmand-Ollivier I, Mosquet B, et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol 2005; 17: 1135-7.
67. Bonkovsky HL. Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 2006; 144: 68-71.
68. Javaid A, Bonkovsky HL. Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern. J Hepatol 2006; 45: 334-5.
69. Jimemez-Saenz M, Martinez-Sanchez C. Acute hepatitis associated with the use of green tea infusions. J Hepatol 2006; 44: 616-7.
70. Martinez-Sierra C. Rendon Unceta P, Martin Herrera L. Acute hepatitis after green tea ingestion. Med Clin (Barc) 2006; 127: 119.
71. Molinari M, Watt KD, Kruszyna T, et al. Acute liver failure induced by green tea extracts: case reports and review of the literature. Liver Transpl 2006; 12: 1892-5.
72. Björnsson E, Olson R. Serious adverse liver reactions associated with herbal weight loss supplements. J Hepatol 2007; 47: 295-7.
73. Frederico A, Tiso A, Loguercio C. A case of hepatotoxicity caused by green tea. Free Rad Biol Med 2007; 43: 474.
74. Sarma DN, Barrett ML, Chavez ML, et al. Safety of green tea extract: a systematic review by the US Pharmacopeia. Drug Saf 2008; 31: 469-84.
75. Liss G, Lewis JH. Drug-induced liver injury: what was new in 2008? Expert Opin Drug Metab Toxicol 2009; 5: 843-60.
76. Mazzanti G, Menniti-Ippolito F, Moro PA, et al. Hepatotoxicity from green tea: a review of the literature and two unpublished cases. Eur J Clin Pharmacol 2009; 65: 331-41.
77. Verheist X, Burvenich P, Van Sassenbroeck D, et al. Acute hepatitis after treatment for hair loss with oral green tea extracts (Camellia sinensis). Acta Gastroenterol Belg 2009; 72: 262-4.
78. Rohde J, Jacobsen C, Kromann-Andersen H. Toxic hepatitis triggered by green tea. Ugeskr Laeger 2011; 173: 205-6.
79. Teschke R, Schmidt-Taenzer W, Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver unspecific Naranjo scale precise enough to ascertain causality? Pharmacoepidemiol Drug Saf 2011; 20: 567-82.
80. Teschke R, Schmidt-Taenzer W, Wolff A. USP suspected herbal hepatotoxicity: quality of causality assessment is more important than quantity of counted cases, not vice versa. Pharmacoepidemiol Drug Saf 2012; 21: 336-8.
81. Teschke R, Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf 2012; DOI: 10.2165/11631960-000000000-00000 [Epub ahead of print].
82. Stillman AS, Huxtable R, Consroe P, Kohnen P, Smith S. Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroenterology 1977; 73: 349-52.
83. Fox DW, Hart MC, Bergeson PS, et al. Pyrrolizidine (Senecio) intoxication mimicking Reye syndrome. J Pediatr 1978; 93: 980-2.
84. Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008; 14: 6999-7004.
85. Mohabbat O, Younos MS, Merzad AA, et al. An outbreak of hepatic veno-occlusive disease in north-western Afghanistan. Lancet 1976; 308: 269-71.
86. Datta DV, Khuroo MS, Mattocks AR, Aikat BK, Chhuttani PN. Herbal medicines and veno-occlusive disease in India. Postgrad Med J 1978; 54: 511-5.
87. Tandon HD, Tandon BN, Mattocks AR. An epidemic of veno-occlusive disease of the liver in Afghanistan. Am J Gastroenterol 2008; 70: 607-13.
88. Kakar F, Akbarian Z, Leslie T, et al. An outbreak of hepatic veno-occlusive disease in western Afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids. J Toxicol 2010; 2010: 313280.
89. Hoffmann M, Marbet UA, Hurni A, Bianchi L, Göldi H. Rezidiv einer medikamentös-toxischen Hepatitis: Schweiz Med Forum 2005; 5: 147-8.
90. Duque JM, Ferreiro J, Salgueiro E, Manso G. Hepatotoxicity associated with the consumption of herbal slimming products. Med Clin (Barc) 2007; 128: 238-9.
91. Elinav E, Pinsker G, Safadi R, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol 2007; 47: 514-20.
92. Schoepfer AM, Engel A, Fattinger K, et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol 2007; 47: 521-6.
93. Chao S, Anders M, Turbay M, et al. Toxic hepatitis by consumption of Herbalife products: a case report. Acta Gastroenterol Latinoam 2008; 38: 274-7.
94. Manso G, López-Rivaz L, Duque JM, Salgueiro E. Spanish reports of hepatotoxicity associated with Herbalife. J Hepatol 2008; 49: 289-90. Author reply 290-292
95. Stickel F, Droz S, Patsenker E, et al. Severe hepatotoxicity following ingestion of Herbalife nutritionally supplements contaminated with Bacillus subtilis. J Hepatol 2009; 50: 111-7.
96. Jóhannsson M, Ormarsdóttir S, Olafsson S. Hepatotoxicity associated with the use of Herbalife. Laeknabladid 2010; 96: 167-72.
97. Chen GC, Ramanathan VS, Law D, et al. Acute liver injury induced by weight-loss herbal supplements. World J Hepatol 2010; 2: 410-5.
98. Appelhans K, Smith C, Bejar E, Henig YS. Revisiting acute liver injury associated with Herbalife products. World J Hepatol 2011; 3: 275-7.
99. Manso G, López-Rivas L, Salgueiro ME, et al. Continuous reporting of new cases in Spain supports the relationship between Herbalife products and liver injury. Pharmacoepidemiol Drug Saf 2011; 20: 1080-7.
100. Appelhans K, Frankos V, Shao A. Misconceptions regarding association between Herbalife products and liver related case reports in Spain. Pharmacoepidemiol Drug Saf 2012; 21: 333-4.
101. Manso G. Author's reply. Pharmacoepidemiol Drug Saf 2012; 21: 335.
102. Bae SH, Kim DH, Bae YS, et al. Toxic hepatitis associated with Polygoni multiflori. Korean J Hepatol 2010; 16: 182-6.
103. Stevens T, Qadri A, Zein NN. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. Ann Intern Med 2005; 14: 477-8.
104. Jones FJ, Andrews AH. Acute liver injury associated with the herbal supplement hydroxycut in a soldier deployed to Iraq. Am J Gastroenterol 2007; 102: 2357-8.
105. Shim M, Saab S. Severe hepatotoxicity due to Hydroxycut: a case report. Dig Dis Sci 2009; 54: 406-8.
106. Fong TL, Klontz KC, Canas-Coto A, et al. Hepatotoxicity due to Hydroxycut: a case series. Am J Gastroenterol 2010; 105: 1561-6.
107. Wainwright J, Schonland MM. Toxic hepatitis in black patients in Natal. S Afr Med J 1977; 51: 571.
108. Wainwright J, Schonland MM, Candy HA. Toxicity of Callilepis laureola. S Afr Med J 1977; 52: 313-5.
109. Popat A, Shear NH, Malkiewicz I, et al. The toxicity of Callilepis laureola, a South African traditional herbal medicine. Clin Biochem 2001; 34: 229-36.
110. Kumana CR, Ng M, Lin HJ, et al. Hepatic veno-occlusive disease due to toxic alkaloid in herbal tea. Lancet 1983; II: 1360-1.
111. Fraquelli M, Colli A, Cocciolo M, Conte D. Adult syncytial giant cell chronic hepatitis due to herbal remedy. J Hepatol 2000; 33: 505-8.
112. Woolf GM, Petrovic LM, Rojter SE, et al. Acute hepatitis associated with the Chinese herbal product Jin Bu Huan. Ann Intern Med 1994; 121: 729-35.
113. Horowitz RS, Feldhaus K, Dart RC, Stermitz FR, Beck JJ. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med 1996; 156: 899-903.
114. Picciotti A, Campo N, Brizzolara R, et al. Chronic hepatitis induced by Jin Bu Huan. J Hepatol 1998; 28: 165-7.
115. Gunawan B, Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004; 36: 301-12.
116. Brauer RB, Pfab R, Becker K, Berger H, Stangl M. Fulminantes Leberversagen nach Einnahme des pflanzlichen Heilmittels Kava-Kava. Z Gastroenterologie 2001; 39: 30.
117. Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with kava, a herbal remedy for anxiety. Br Med J 2001; 322: 139.
118. Kraft M, Spahn TW, Menzel J, et al. Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. Dtsch Med Wschr 2001; 126: 970-2 (Article in German).
119. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-9.
120. Saß M, Schnabel S, Kröger J, Liebe S, Schareck WD. Akutes Leberversagen durch Kava Kava - eine seltene Indikation zur Lebertransplantation. Z Gastroenterologie 2001; 39: 29. (in German).
121. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany). Rejection of Drug Risks, Step II. As related to: Kava-Kava (Piper methysticum)-containing, and kavain-containing drugs, including homeopathic preparations with a final concentration up to, and including D4. June 14, 2002. Available at: http://www.spc.int/cis/documents/02_0714_BfArM_Kava_Removal.pdf Last accessed on May 18, 2012.
122. Bujanda L, Palacios A, Silvariño R, Sánchez A, Muñoz C. Hepatitis aguda icterica secundaria a kava. Gastroenterol Hepatol 2002; 25: 434-5.
123. Denham A, McIntyre M, Whitehouse J. Kava - the unfolding story: report on a work-in-progress. J Altern Complement Med 2002; 8: 237-63.
124. Weise B, Wiese M, Plötner A, Ruf BR. Toxic hepatitis after intake of kava-kava. Verdauungskrankheiten 2002; 4: 166-9.
125. Teschke R. Hepatotoxicity of kava-kava: risk factors and prevention. Dtsch Ärztebl 2002; 99: A-3411-8 (Article in German).
126. Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PW. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2003; 178: 442-3.
127. Humberston CL, Akhtar J, Krenzelok EP. Acute hepatitis induced by kava kava J Toxicol/. Clin Toxicol 2003; 41: 109-13.
128. Russmann S, Barguil Y, Cabalion P, et al. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol 2003; 15: 1033-6.
129. Schulze J, Raasch W, Siegers CP. Toxicity of kava pyrones, drug safety and precautions- a case study. Phytomedicine 2003; 10, Suppl IV: 68-73.
130. Stickel F, Baumüller HM, Seitz K, et al. Hepatitis induced by kava (Piper methysticum rhizoma). J Hepatol 2003; 39: 62-7.
131. Teschke, R Kava, kavapyrones and toxic liver injury. Z Gastroenterol 2003; 41: 395-404 (Article in German)
132. Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 2003; 10: 440-6.
133. Schmidt M, Morgan M, Bone K, McMillan J. Kava: a risk-benefit assessment. In: Mills M, Bone K, eds. The Essential Guide to Herbal Safety. St Louis (Missouri): Elsevier Churchill Livingstone, 2005; 155-221.
134. World Health Organization. Assessments of the Risk of Hepatotoxicity with Kava Products. Geneva, Switzerland: WHO Document Production Services, 2007.
135. Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-93.
136. Teschke R, Schwarzenboeck A, Akinci A. Kava hepatotoxicity: a European view. New Zeal Med J 2008; 121: 1283 Available at: http://www.nzma.org.nz/journal/121-1283/3296/ Accessed May 18, 2012.
137. Christl SU, Seifert A, Seeler D. Toxic hepatitis after consumption of traditional kava preparation. Int Soc Trav Med 2009; 16: 55-6.
138. Teschke R, Wolff A. Kava hepatotoxicity: regulatory data selection and causality assessment. Dig Liv Dis 2009; 41: 891-901.
139. Teschke R, Wolff A. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate? Regul Toxicol Pharmacol 2011; 59: 1-7.
140. Teschke R. Kava hepatotoxicity: a clinical review. Ann Hepatol 2010; 9: 251-65.
141. Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 2010; 30: 1270-9.
142. Teschke R, Schulze J. Risk of kava hepatotoxicity and the FDA consumer advisory. J Am Med Ass 2010; 304: 2174-5.
143. Teschke R, Lebot V. Proposal for a Kava Quality Standardization Code. Food Chem Toxicol 2011; 49: 2503-16.
144. Rowe A, Ramzan I. Letter to the Editor: are mould hepatotoxins responsible for kava hepatotoxicity? Phytother Res 2012; DOI: 10.1002/ptr.4642 [Epub ahead of print].
145. Teschke R, Sarris J, Schweitzer I. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol 2012; 73: 170-4.
146. Teschke R, Sarris J, Lebot V. Contaminant hepatotoxins as culprits for hepatotoxicity - fact or fiction? Phytother Res 2012; DOI: 10.1002/ptr.4729 [Epub ahead of print].
147. Nadir A, Agrawal S, King PD, Marshall JB. Acute hepatitis associated with the use of a Chinese herbal product, ma-huang. Am J Gastroenterol 1996; 91: 1436-8.
148. Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of Ma Huang. Am J Gastroenterol 2001; 96: 1654-5.
149. McGee J, Patrick RS, Wood CB, Blumgart LH. A case of veno-occlusive disease of the liver in Britain associated with herbal tea consumption. J Clin Pathol 1976; 29: 788-94.
150. Harvey J, Colin-Jones DG. Mistletoe hepatitis. Br Med J (Clin Res Ed) 1981; 282: 186-7.
151. Hyde FF. Mistletoe hepatitis. Br Med J 1981; 282: 739.
152. Colin-Jones DG, Harvey J. Mistletoe hepatitis. Br Med J 1982; 284: 744-5.
153. Farnsworth NR, Loub WD. Mistletoe hepatitis. Br Med J 1982; 283: 1058.
154. Stirpe F. Mistletoe hepatitis. Br Med J 1983; 1: 29.
155. Millonig G, Stadlmann S, Vogel W. Herbal hepatotoxicity: acute hepatitis caused by a Noni preparation (Morinda citrifolia). Eur J Gastroenterol Hepatol 2005; 17: 445-7.
156. Stadlbauer V, Fickert P, Lackner C, et al. Hepatotoxicity of NONI juice: report of two cases. World J Gastroenterol 2005; 11: 4758-60.
157. Yüce B, Gülberg V, Diebold J, Gerbes AL. Hepatitis induced by Noni juice from Morinda citrifolia: a rare cause of hepatotoxicity or the tip of a iceberg? Digestion 2006; 73: 167-70.
158. López-Cepero Andrada JM, Lerma Castilla S, Fernandèz Olvera MD, Amaya Vidal A. Hepatotoxicity caused by a Noni (Morinda citrifolia) preparation. Espanola de Patologia Digestiva 2007; 99: 179-81 (Article in Spanish).
159. Stadlbauer V, Weiss S, Payer F, Stauber RE. Herbal does not at all mean innocuous: the sixth case of hepatotoxicity associated with Morinda citrifolia (Noni). Am J Gastroenterol 2008; 103: 2406-7.
160. Yu EL, Sivagnanam M, Ellis L, Huang JS. Acute hepatotoxicity after ingestion of Morinda citrifolia (Noni Berry) juice in a 14-year-old boy. J Pedriat Gastroenterol Nutr 2011; 52: 222-4.
161. Altan E, Bitik B, Kalpkci Y, Dogan E, Altundag K. Probable hepatotoxicity related to Nerium oleander extract in a patient with metastatic synovial sarcoma of the knee. J Altern Compl Med 2009; 15: 113.
162. Mokhobo KP. Herb use and necrodegenerative hepatitis. S Afr Med J 1976; 50: 1096-9.
163. Vallance WB. Pennyroyal poisoning: a fatal case. Lancet 1955; 22: 850.
164. Sullivan JB, Rumack BH, Thomas H, Peterson RG, Bryson P. Pennyroyal oil poisoning and hepatotoxicity. J Am Med Ass 1979; 242: 2873-974.
165. Anderson IB, Mullen WH, Meeker JE, et al. Pennyroyal toxicity: measurement of toxic metabolite levels in two cases and review o the literature. Ann Intern Med 1996; 124: 726-34.
166. Bakerink JA, Gospe SM, Dimand RJ, Eldridge MW. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics 1996; 98: 944-7.
167. Joshi D, Cross TJS, Wong VS. Acute drug induced hepatitis secondary to a weight loss product purchased over the internet. Nutr J 2007; 6: 13.
168. Tandon RK, Tandon BN, Tandon HD. Study of an epidemic of venoocclusive disease in India. Gut 1976; 17: 849-55.
169. Tandon BN, Tandon HD, Tandon RK, Narndranathan M, Joshi YK. An epidemic of veno-occlusive disease of the liver in central India. Lancet 1976; 308: 272.
170. Roselle H, Ekatan A, Tzeng J, Sapienza M, Kocher J. Symptomatic hepatitis associated with the use of herbal Red Yeast Rice. Ann Intern Med 2008; 149: 516-7.
171. Larrey D. Hepatotoxicity of herbal remedies. J Hepatol 1997; 26 (Suppl.1): 47-51.
172. Zimmerman HJ. Hepatotoxicity. Philadelphia: Lippincott Williams & Wilkins, 1999.
173. Lapi F, Gallo E, Giocaliere E, et al. Acute liver damage due to Serenoa repens: a case report. Br J Clin Pharmacol 2010; 69: 558-60.
174. MacGregor FB, Abernethy VE, Dahabra S, Cobden I, Hayes PC. Hepatotoxicity of herbal remedies. Br Med J 1989; 299: 1156-7.
175. Caldwell SH, Feeley JW, Wieboldt TF, Featherston PL, Dickson RC. Acute hepatitis with use of over-the-counter herbal remedies. Va Med Q 1994; 121: 31-3.
176. Hullar TE, Sapers BL, Ridker PM, et al. Herbal toxicity and fatal hepatic failure (letter). Am J Med 1999; 106: 267-8.
177. Beuers U, Spengler U, Pape GR. Hepatitis after chronic abuse of senna. Lancet 1991; 337: 372-3.
178. Seybold U, Landauer L, Hillebrand S, Goebel FD. Senna-induced hepatitis in a poor metabolizer. Ann Intern Med 2004; 141: 650-1.
179. Vanderperren B, Rizzo M, Angenot L, et al. Acute liver failure with renal impairment related to the abuse of Senna anthraquinone glycosides. Ann Pharmacother 2005; 39: 1353-7.
180. Cardenas A, Restrepo JC, Sierra F, Correa G. Acute hepatitis due to shen-min: a herbal product derived from Polygonum multiforum. J Clin Gastroent 2006; 40: 629-32.
181. Panis B, Wong DR, Hooymans PM, et al. Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese hebal preparation. J Pediat Gastroenterol Nutr 2005; 41: 256-8.
182. Jung KA, Min HJ, Yoo SS, et al. Drug-induced liver injury: twenty-five cases of acute hepatitis following ingestion of Polygonum multiflorum Thun. Gut Liver 2011; 5: 493-9.
183. Wu GL, Yu GY, Chen J. Clinical analysis of hepatic veno-occlusive disease induced by Sedum aizoon. Zhongguo Zhong Yao Za Zhi 2008; 33: 2402-4 (Article in Chinese).
184. Mennecier D, Saloum T, Dourthe PM, et al. Acute hepatitis after phytotherapy. Présse Med 1999; 28: 966.
185. De Smet PAGM, Van Den Eertwegh AJM, Lesterhuis W, Stricker BHC. Hepatotoxicity associated with herbal tablets. BMJ 1996; 313: 92.
186. Takegoshi K, Tohyama T, Okuda K, Suzuki K, Ohta G. A case of Venoplant-induced hepatic injury. Gastroenterologica Japonica 1986; 21: 62-5.
187. Mathieu N, Bouallegue L, Mognol P, Vallot T, Soule JC. Hepatic toxicity probably due to X-elles in phytotherapy. Gastroenterol Clin Biol 2005; 29: 1188-9.
188. Itoh S, Marutani K, Nishijima T, Matsuo S, Itabashi M. Liver injuries induced by herbal medicine, Syo-saiko-to (xiao-chai-hu-tang). Dig Dis Sci 1995; 40: 1845-8.
189. Hsu LM, Huang YS, Tsay SH, Chang FY, Lee SD. Acute hepatitis induced by Chinese hepatoprotective herb xiao-chai-hu-tang. J Chin Med Ass 2006; 69: 86-8.
190. Malhotra U, Rakita R, Fernandez F, et al. Hepatitis temporarily associated with an herbal supplement containing Artemisin-Washington, 2008. J Am Med Ass 2009; 302: 1412-4.
191. Favreau JT, Ryu ML, Braunstein G, et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 2002; 136: 590-5.
192. Durazo FA, Lassman C, Han SHB, et al. Fulminant liver failure due to usnic acid for weight loss. Am J Gastroenterol 2004; 99: 950-2.
193. Sanchez W, Maple JT, Burgart LJ, Kamath PS. Severe hepatotoxicity associated with use of a dietary supplement containing usnic acid. Mayo Clin Proc 2006; 81: 541-4.
194. Chitturi S, Farrell GC. Hepatotoxic slimming aids and other herbal hepatotoxins. J Gastroenterol Hepatol 2009; 23: 366-73.
195. Mukai H, Watanabe T, Ando M, Katsumata N. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn J Clin Oncol 2006; 36: 808-10.
196. Ossendza RA, Grandval P, Chinoune F, et al. Acute cholestatic hepatitis due to glucosamine forte. Gastroenterol Clin Biol 2007; 31: 449-50.
197. Fujii H, Takagaki N, Yoh T, et al. Non-prescription supplement-induced hepatitis with hyperferritinemia and mutation (H63D) in the HFG gene. Hepatol Res 2008; 38: 319-23.
198. Smith A, Dillon J. acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies. BMJ Case Reports 2009; doi:10.1136/bcr.02.2009.1603Accessed May 18, 2012.
199. Son HS, Kim GS, Lee SW, et al. Toxic hepatitis associated with carp juice ingestion. Korean J Hepatol 2006; 12: 103-6.
200. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann KH. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol 2011; 11: 249-59.
201. Teschke R, Frenzel C, Schulze J, Eickhoff A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regul Toxicol Pharmacol 2012; 63: 1-9.
202. Teschke R, Frenzel C, Wolff A, et al. Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvements. Ann Hepatol 2012; 11: 500-12.
203. Piccolo P, Gentile S, Alegiani F, Angelico M. Severe drug induced acute hepatitis associated with use of St John's wort during treatment with pegylated interferon. BMJ Case Reports 2009;. doi:10.1136/bcr.08.2008.0761 Accessed May 18, 2012.
204. Danan G, Bénichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-30.
205. Bénichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-6.
206. Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008; 66: 758-66.
207. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
208. WHO. Causality assessment of suspected adverse reactions. WHO Collaboratoring Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC). Database, 2000. Available at: http://www.who-umc.org/DynPage.aspx?id=22682 Accessed May 18, 2012.
209. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33: 308-10.
210. García-Cortés M, Stephens C, Lucena MI, Fernández-Castañer A, Andrade RJ. on behalf of the Spanish Group for the Study of Drug-Induced Liver Disease. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011; 55: 683-91.